Personalized Lens Correction Improves Quantitative Fundus Autofluorescence Analysis.

"Disclosure: L. von der Emde, Heidelberg Engineering (R); G.C. Rennen, BONFOR O-137.0031, Faculty of Medicine, University of Bonn, Bonn, Germany; M. Vaisband, None; J. Hasenauer, None; R. Liegl, None; M. Fleckenstein, US20140303013 A1 (P), Novartis (R), Bayer (R), Genentech (R), Roche (R); M. Pfau, Apellis (C, F), Boehringer Ingelheim (C), Astherna (C), iCare (F), Novartis (R); F.G. Holz, Acucela (C, F), Allergan (F), Apellis (C, F), Bayer (C, F), Boehringer-Ingelheim (C), Bioeq/Formycon (F, C), CenterVue (F), Ellex (F), Roche/Genentech (C, F), Geuder (C, F), Graybug (C), Gyroscope (C), Heidelberg Engineering (C, F), IvericBio (C, F), Kanghong (C, F), LinBioscience (C), NightStarX (F), Novartis (C, F), Optos (F), Oxurion (C), Pixium Vision (C, F), Oxurion (C), Stealth BioTherapeutics (C), Zeiss (F, C); T. Ach, Apellis (C), Bayer (C), Roche (C), Novartis (C), Novartis (R)"

"Supported by the Jackstädt Foundation L. von der Emde, National Institutes of Health Core Grant (EY014800), and an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah to M. Fleckenstein, NIH/NEI R01EY027948 (T. Ach), University of Bonn Bonfor #O-137.0031."